Skip to main content
Top
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Study protocol

Improving the quality and efficiency of follow-up after curative treatment for breast cancer – rationale and study design of the MaCare trial

Authors: Merel L Kimman, Adri C Voogd, Carmen D Dirksen, Paul Falger, Pierre Hupperets, Kristien Keymeulen, Marlene Hebly, Cary Dehing, Philippe Lambin, Liesbeth J Boersma

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

After curative treatment for breast cancer women frequently attend scheduled follow-up examinations. Usually the follow-up is most frequent in the first 2–3 years (2–4 times a year); thereafter the frequency is reduced to once a year in most countries. Its main aim is to detect local disease recurrence, or a second primary breast cancer, but also to provide information and psychosocial support. However, the cost-effectiveness of these frequent visits is under much debate, leading to a search for less intensive and more cost-effective follow-up strategies.
In this paper the design of the MaCare trial is described. This trial compares the cost-effectiveness of four follow-up strategies for curatively treated breast cancer patients. We investigate the costs and effects of nurse-led telephone follow-up and a short educational group programme.

Methods/design

The MaCare trial is a multi centre randomised clinical trial in which 320 breast cancer patients are randomised into four follow-up strategies, focussed on the first 18 months after treatment: 1) standard follow-up; 2) nurse-led telephone follow-up; 3) arm 1 with the educational group programme; 4) arm 2 with the educational group programme. Data is collected at baseline and 3, 6, 12 and 18 months after treatment. The primary endpoint of the trial is cancer-specific quality of life as measured by the global health/QoL scale of the EORTC QLQ-C30. Secondary outcomes are perceived feelings of control, anxiety, patients' satisfaction with follow-up and costs. A cost-effectiveness analysis will be performed from a societal perspective.

Discussion

Reduced follow-up strategies for breast cancer have not yet been widely applied in clinical practice. Improvement of psychosocial support and information to patients could lead to a better acceptance of reduced follow-up. The MaCare trial combines a reduced follow-up strategy with additional psychosocial support. Less frequent follow-up can reduce the burden on medical specialists and costs. The educational group programme can improve QoL of patients, but also less frequent follow-up can improve QoL by reducing the anxiety experienced for each follow-up visit. Results of the trial will provide knowledge on both costs and psychosocial aspects regarding follow-up and are expected in 2009.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108.CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108.CrossRefPubMed
2.
go back to reference Rutgers EJ, van Slooten EA, Kluck HM: Follow-up after treatment of primary breast cancer. Br J Surg. 1989, 76: 187-190.CrossRefPubMed Rutgers EJ, van Slooten EA, Kluck HM: Follow-up after treatment of primary breast cancer. Br J Surg. 1989, 76: 187-190.CrossRefPubMed
3.
go back to reference Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, Palli D, del Roselli TM, Liberati A: Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005, CD001768- Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, Palli D, del Roselli TM, Liberati A: Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005, CD001768-
4.
go back to reference Brada M: Is there a need to follow-up cancer patients?. Eur J Cancer. 1995, 31A: 655-657. 10.1016/0959-8049(95)00079-X.CrossRefPubMed Brada M: Is there a need to follow-up cancer patients?. Eur J Cancer. 1995, 31A: 655-657. 10.1016/0959-8049(95)00079-X.CrossRefPubMed
5.
go back to reference Dewar JA, Kerr GR: Value of routine follow up of women treated for early carcinoma of the breast. Br Med J (Clin Res Ed). 1985, 291: 1464-1467.CrossRef Dewar JA, Kerr GR: Value of routine follow up of women treated for early carcinoma of the breast. Br Med J (Clin Res Ed). 1985, 291: 1464-1467.CrossRef
6.
go back to reference Schapira DV: Breast cancer surveillance - a cost-effective strategy. Breast Cancer Res Treat. 1993, 25: 107-111. 10.1007/BF00662135.CrossRefPubMed Schapira DV: Breast cancer surveillance - a cost-effective strategy. Breast Cancer Res Treat. 1993, 25: 107-111. 10.1007/BF00662135.CrossRefPubMed
7.
go back to reference Jacobs HJ, van Dijck JA, de Kleijn EM, Kiemeney LA, Verbeek AL: Routine follow-up examinations in breast cancer patients have minimal impact on life expectancy: a simulation study. Ann Oncol. 2001, 12: 1107-1113. 10.1023/A:1011624829512.CrossRefPubMed Jacobs HJ, van Dijck JA, de Kleijn EM, Kiemeney LA, Verbeek AL: Routine follow-up examinations in breast cancer patients have minimal impact on life expectancy: a simulation study. Ann Oncol. 2001, 12: 1107-1113. 10.1023/A:1011624829512.CrossRefPubMed
8.
go back to reference GIVIO: Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. Jama. 1994, 271: 1587-1592. 10.1001/jama.271.20.1587.CrossRef GIVIO: Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. Jama. 1994, 271: 1587-1592. 10.1001/jama.271.20.1587.CrossRef
9.
go back to reference Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V: Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. Jama. 1994, 271: 1593-1597. 10.1001/jama.271.20.1593.CrossRefPubMed Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V: Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. Jama. 1994, 271: 1593-1597. 10.1001/jama.271.20.1593.CrossRefPubMed
10.
go back to reference Pennery E, Mallet J: A preliminary study of patients' perceptions of routine follow-up after treatment for breast cancer. Eur J Oncol Nurs. 2000, 4: 138-45; discussion 146-7. 10.1054/ejon.2000.0092.CrossRefPubMed Pennery E, Mallet J: A preliminary study of patients' perceptions of routine follow-up after treatment for breast cancer. Eur J Oncol Nurs. 2000, 4: 138-45; discussion 146-7. 10.1054/ejon.2000.0092.CrossRefPubMed
11.
go back to reference Allen A: The meaning of the breast cancer follow-up experience for the women who attend. Eur J Oncol Nurs. 2002, 6: 155-161. 10.1054/ejon.2002.0175.CrossRefPubMed Allen A: The meaning of the breast cancer follow-up experience for the women who attend. Eur J Oncol Nurs. 2002, 6: 155-161. 10.1054/ejon.2002.0175.CrossRefPubMed
12.
go back to reference Gulliford T, Opomu M, Wilson E, Hanham I, Epstein R: Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. Bmj. 1997, 314: 174-177.CrossRefPubMedPubMedCentral Gulliford T, Opomu M, Wilson E, Hanham I, Epstein R: Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. Bmj. 1997, 314: 174-177.CrossRefPubMedPubMedCentral
13.
go back to reference Grunfeld E, Levine MN, Julian JA, Coyle D, Szechtman B, Mirsky D, Verma S, Dent S, Sawka C, Pritchard KI, Ginsburg D, Wood M, Whelan T: Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol. 2006, 24: 848-855. 10.1200/JCO.2005.03.2235.CrossRefPubMed Grunfeld E, Levine MN, Julian JA, Coyle D, Szechtman B, Mirsky D, Verma S, Dent S, Sawka C, Pritchard KI, Ginsburg D, Wood M, Whelan T: Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol. 2006, 24: 848-855. 10.1200/JCO.2005.03.2235.CrossRefPubMed
14.
go back to reference Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, Fitzpatrick R, Vessey M: Routine follow up of breast cancer in primary care: randomised trial. Bmj. 1996, 313: 665-669.CrossRefPubMedPubMedCentral Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, Fitzpatrick R, Vessey M: Routine follow up of breast cancer in primary care: randomised trial. Bmj. 1996, 313: 665-669.CrossRefPubMedPubMedCentral
15.
go back to reference Brown L, Payne S, Royle G: Patient initiated follow up of breast cancer. Psychooncology. 2002, 11: 346-355. 10.1002/pon.576.CrossRefPubMed Brown L, Payne S, Royle G: Patient initiated follow up of breast cancer. Psychooncology. 2002, 11: 346-355. 10.1002/pon.576.CrossRefPubMed
16.
go back to reference Koinberg IL, Fridlund B, Engholm GB, Holmberg L: Nurse-led follow-up on demand or by a physician after breast cancer surgery: a randomised study. Eur J Oncol Nurs. 2004, 8: 109-17; discussion 118-20. 10.1016/j.ejon.2003.12.005.CrossRefPubMed Koinberg IL, Fridlund B, Engholm GB, Holmberg L: Nurse-led follow-up on demand or by a physician after breast cancer surgery: a randomised study. Eur J Oncol Nurs. 2004, 8: 109-17; discussion 118-20. 10.1016/j.ejon.2003.12.005.CrossRefPubMed
17.
go back to reference de Bock GH, Bonnema J, Zwaan RE, van de Velde CJ, Kievit J, Stiggelbout AM: Patient's needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer. 2004, 90: 1144-1150. 10.1038/sj.bjc.6601655.CrossRefPubMed de Bock GH, Bonnema J, Zwaan RE, van de Velde CJ, Kievit J, Stiggelbout AM: Patient's needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer. 2004, 90: 1144-1150. 10.1038/sj.bjc.6601655.CrossRefPubMed
18.
go back to reference Clark MM, Bostwick JM, Rummans TA: Group and individual treatment strategies for distress in cancer patients. Mayo Clin Proc. 2003, 78: 1538-1543.CrossRefPubMed Clark MM, Bostwick JM, Rummans TA: Group and individual treatment strategies for distress in cancer patients. Mayo Clin Proc. 2003, 78: 1538-1543.CrossRefPubMed
19.
go back to reference Gijsen BCM, Koppejan-Rensenbrink AG: Herstel & Balans, groepsrevalidatie in de oncologie. Tijdschrift Kanker. 2003, 27: 36-39. Gijsen BCM, Koppejan-Rensenbrink AG: Herstel & Balans, groepsrevalidatie in de oncologie. Tijdschrift Kanker. 2003, 27: 36-39.
20.
go back to reference Nagel GC, Schmidt S, Strauss BM, Katenkamp D: Quality of life in breast cancer patients: a cluster analytic approach. Empirically derived subgroups of the EORTC-QLQ BR 23--a clinically oriented assessment. Breast Cancer Res Treat. 2001, 68: 75-87. 10.1023/A:1017975609835.CrossRefPubMed Nagel GC, Schmidt S, Strauss BM, Katenkamp D: Quality of life in breast cancer patients: a cluster analytic approach. Empirically derived subgroups of the EORTC-QLQ BR 23--a clinically oriented assessment. Breast Cancer Res Treat. 2001, 68: 75-87. 10.1023/A:1017975609835.CrossRefPubMed
21.
go back to reference Osoba D, Rodrigues G, Myles J, Zee B, Pater J: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998, 16: 139-144.PubMed Osoba D, Rodrigues G, Myles J, Zee B, Pater J: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998, 16: 139-144.PubMed
22.
go back to reference Lazarus RS, Folkman S: Stress, Appraisal and Coping. 1984, New York, Guilford Lazarus RS, Folkman S: Stress, Appraisal and Coping. 1984, New York, Guilford
23.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993, 85: 365-376. 10.1093/jnci/85.5.365.CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993, 85: 365-376. 10.1093/jnci/85.5.365.CrossRefPubMed
24.
go back to reference Pearlin LI, Schooler C: The structure of coping. J Health Soc Behav. 1978, 19: 2-21. 10.2307/2136319.CrossRefPubMed Pearlin LI, Schooler C: The structure of coping. J Health Soc Behav. 1978, 19: 2-21. 10.2307/2136319.CrossRefPubMed
25.
go back to reference van der Ploeg HM: Validatie van de Zelf-Beoordelings Vragenlijst (een Nederlandstalige bewerking van de Spielberger State-Trait Anxiety Inventory). Nederlands Tijdschrift voor de Psychologie. 1980, 35: 243-249. van der Ploeg HM: Validatie van de Zelf-Beoordelings Vragenlijst (een Nederlandstalige bewerking van de Spielberger State-Trait Anxiety Inventory). Nederlands Tijdschrift voor de Psychologie. 1980, 35: 243-249.
26.
go back to reference Hagedoorn M, Uijl SG, Van Sonderen E, Ranchor AV, Grol BM, Otter R, Krol B, Van den Heuvel W, Sanderman R: Structure and reliability of Ware's Patient Satisfaction Questionnaire III: patients' satisfaction with oncological care in the Netherlands. Med Care. 2003, 41: 254-263. 10.1097/00005650-200302000-00007.PubMed Hagedoorn M, Uijl SG, Van Sonderen E, Ranchor AV, Grol BM, Otter R, Krol B, Van den Heuvel W, Sanderman R: Structure and reliability of Ware's Patient Satisfaction Questionnaire III: patients' satisfaction with oncological care in the Netherlands. Med Care. 2003, 41: 254-263. 10.1097/00005650-200302000-00007.PubMed
27.
go back to reference Group EQ: EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990, 16: 199-208. 10.1016/0168-8510(90)90421-9.CrossRef Group EQ: EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990, 16: 199-208. 10.1016/0168-8510(90)90421-9.CrossRef
28.
go back to reference Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M: Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001, 345: 1378-1387. 10.1056/NEJMoa010874.CrossRefPubMed Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M: Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001, 345: 1378-1387. 10.1056/NEJMoa010874.CrossRefPubMed
29.
go back to reference Dolan P: Modeling valuations for EuroQol health states. Med Care. 1997, 35: 1095-1108. 10.1097/00005650-199711000-00002.CrossRefPubMed Dolan P: Modeling valuations for EuroQol health states. Med Care. 1997, 35: 1095-1108. 10.1097/00005650-199711000-00002.CrossRefPubMed
30.
go back to reference Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-effectiveness in health and medicine. 1996, New York, Oxford University Press Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-effectiveness in health and medicine. 1996, New York, Oxford University Press
31.
go back to reference Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH: Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. 2004, Diemen, College voor zorgverzekeringen Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH: Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. 2004, Diemen, College voor zorgverzekeringen
32.
go back to reference Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L: The friction cost method for measuring indirect costs of disease. J Health Econ. 1995, 14: 171-189. 10.1016/0167-6296(94)00044-5.CrossRefPubMed Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L: The friction cost method for measuring indirect costs of disease. J Health Econ. 1995, 14: 171-189. 10.1016/0167-6296(94)00044-5.CrossRefPubMed
Metadata
Title
Improving the quality and efficiency of follow-up after curative treatment for breast cancer – rationale and study design of the MaCare trial
Authors
Merel L Kimman
Adri C Voogd
Carmen D Dirksen
Paul Falger
Pierre Hupperets
Kristien Keymeulen
Marlene Hebly
Cary Dehing
Philippe Lambin
Liesbeth J Boersma
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-1

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine